Evidence map›Paper›PMID 24926959›Full record

ArticlePloS one2014

Quantification of functionalised gold nanoparticle-targeted knockdown of gene expression in HeLa cells.

Meesbah Jiwaji, Mairi E Sandison, Julien Reboud, Ross Stevenson, Rónán Daly, Gráinne Barkess, Karen Faulds, Walter Kolch, Duncan Graham, Mark A Girolami and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Meesbah JiwajiInstitute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom; School of Life and Health Science, Aston University, Birmingham, United Kingdom.
Mairi E SandisonInstitute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom; Division of Biomedical Engineering, School of Engineering, University of Glasgow, Glasgow, United Kingdom.
Julien ReboudDivision of Biomedical Engineering, School of Engineering, University of Glasgow, Glasgow, United Kingdom.
Ross StevensonCentre for Molecular Nanometrology, Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow, United Kingdom.
Rónán DalySchool of Computing Science, University of Glasgow, Glasgow, United Kingdom.
Gráinne BarkessInstitute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Karen FauldsCentre for Molecular Nanometrology, Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow, United Kingdom.
Walter KolchInstitute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom; Systems Biology Ireland and the Conway Institute, University College Dublin, Belfield, Dublin, Ireland.
Duncan GrahamCentre for Molecular Nanometrology, Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow, United Kingdom.
Mark A GirolamiSchool of Computing Science, University of Glasgow, Glasgow, United Kingdom; Department of Statistical Science, University College London, London, United Kingdom.
Jonathan M CooperDivision of Biomedical Engineering, School of Engineering, University of Glasgow, Glasgow, United Kingdom.
Andrew R PittInstitute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom; School of Life and Health Science, Aston University, Birmingham, United Kingdom.
University of Glasgow · GBUniversity of Strathclyde · GBUniversity College Dublin · IEUniversity College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGene therapy continues to grow as an important area of research, primarily because of its potential in the treatment of disease. One significant area where there is a need for better understanding is in improving the efficiency of oligonucleotide delivery to the cell and indeed, following delivery, the characterization of the effects on the cell.

methodsIn this report, we compare different transfection reagents as delivery vehicles for gold nanoparticles functionalized with DNA oligonucleotides, and quantify their relative transfection efficiencies. The inhibitory properties of small interfering RNA (siRNA), single-stranded RNA (ssRNA) and single-stranded DNA (ssDNA) sequences targeted to human metallothionein hMT-IIa are also quantified in HeLa cells. Techniques used in this study include fluorescence and confocal microscopy, qPCR and Western analysis.

findingsWe show that the use of transfection reagents does significantly increase nanoparticle transfection efficiencies. Furthermore, siRNA, ssRNA and ssDNA sequences all have comparable inhibitory properties to ssDNA sequences immobilized onto gold nanoparticles. We also show that functionalized gold nanoparticles can co-localize with autophagosomes and illustrate other factors that can affect data collection and interpretation when performing studies with functionalized nanoparticles.

conclusionsThe desired outcome for biological knockdown studies is the efficient reduction of a specific target; which we demonstrate by using ssDNA inhibitory sequences targeted to human metallothionein IIa gene transcripts that result in the knockdown of both the mRNA transcript and the target protein.

Indexed as

DNA, Single-StrandedGene Knockdown TechniquesGoldHeLa CellsHumansMetallothioneinMetal NanoparticlesOligonucleotides, AntisenseRNA, MessengerRNA, Small InterferingTransfectionDNA, Single-StrandedGoldMetallothioneinMT2A protein, humanOligonucleotides, AntisenseRNA, MessengerRNA, Small Interfering

Identifiers

PMID24926959
PMCPMC4057226
OpenAlexW2072654040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.